2015
DOI: 10.1080/21645515.2015.1051276
|View full text |Cite
|
Sign up to set email alerts
|

Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
43
0
4

Year Published

2015
2015
2023
2023

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 64 publications
(49 citation statements)
references
References 9 publications
2
43
0
4
Order By: Relevance
“…It is worth noting, that until recently, MenY was of minor importance among the invasive strains in Europe accounting for less than 2% of reported IMD cases mainly isolated among the elderly. However, an increase of MenY cases has been reported in various European countries since 2010 and a shift to younger age groups was also observed [24]. Similarly, an increase was observed in Greece from 2% (2013) and 3.5% (2014) to 8.1% for 2015 [16].…”
Section: Discussionmentioning
confidence: 95%
“…It is worth noting, that until recently, MenY was of minor importance among the invasive strains in Europe accounting for less than 2% of reported IMD cases mainly isolated among the elderly. However, an increase of MenY cases has been reported in various European countries since 2010 and a shift to younger age groups was also observed [24]. Similarly, an increase was observed in Greece from 2% (2013) and 3.5% (2014) to 8.1% for 2015 [16].…”
Section: Discussionmentioning
confidence: 95%
“…5 Recent evidence indicates that meningococcal serogroup Y (MenY) has continued to increase in northern Europe and the proportion of IMD attributable to MenY remains high in Scandinavian countries, ranging from 26% to 51%. 6 An analysis of consolidated data (referring to 2014) shows that the incidence of IMD in Italy has remained stable in recent years, apart from an unexpected increase in the cases of MenC in young adults was reported in 2015 due to a cluster in Tuscany, which recurred in the early months of 2016. Immunisation campaigns have been implemented as a result, continuously adapting them to the evolution of the epidemiological situation, and IMD surveillance activities have been enhanced.…”
Section: Introductionmentioning
confidence: 99%
“…In the EU area, serogroup B is the predominant cause of IMD, followed by serogroup C, whereas serogroup Y is recently increasing (Bröker et al, 2015;Törös et al, 2014). The only successful meningococcal disease prevention tool is represented by conjugate vaccines, including both meningococcal serogroup C glycoconjugate vaccines and quadrivalent conjugate vaccines against serogroups A, C, Y and W. Moreover, a novel meningococcal multicomponent vaccine, four-component meningococcal serogroup B (4CMenB; Bexsero ® ), has been approved in Europe, Canada, Australia and USA.…”
Section: Introductionmentioning
confidence: 99%